Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)
Close on Nov 17, 2026Market cap $4.78MP/E –Yield –
Cerenome gross margin
Gross margin is gross profit as a percentage of revenue.
Cerenome's gross margin for the twelve months ending Mar 31, 2018 was 15.0%. For fiscal 2018 it was 68.7%, against 5.4% the year before. The highest annual figure on record is 68.7% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 68.7% | +63.3 |
| FY2017 | Dec 31, 2017 | 5.4% | −36.3 |
| FY2016 | Dec 31, 2016 | 41.7% | +7.5 |
| FY2015 | Dec 31, 2015 | 34.1% | −6.5 |
| FY2014 | Dec 31, 2014 | 40.6% | −11.3 |
| FY2013 | Dec 31, 2013 | 52.0% | −2.1 |
| FY2012 | Dec 31, 2012 | 54.1% | +2.1 |
| FY2011 | Dec 31, 2011 | 51.9% | −0.7 |
| FY2010 | Dec 31, 2010 | 52.7% | +10.8 |
| FY2009 | Dec 31, 2009 | 41.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2018 | Mar 31, 2018 | 20.8% | +41.9 |
| Q4 FY2017 | Dec 31, 2017 | 4.4% | −31.2 |
| Q3 FY2017 | Sep 30, 2017 | -4.3% | −19.7 |
| Q2 FY2017 | Jun 30, 2017 | 27.0% | −21.0 |
| Q1 FY2017 | Mar 31, 2017 | -21.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 35.5% | – |
| Q3 FY2016 | Sep 30, 2016 | 15.5% | – |
| Q2 FY2016 | Jun 30, 2016 | 48.0% | – |
See a number that looks wrong?